MiRNA137 Mimics Targeting MCL-1 as a Novel Therapeutic Agent in Preclinical Models of Multiple Myeloma

被引：0
|
作者：
Yang, Y. [1 ]
Saha, M. N. [1 ]
Chen, Y. [1 ]
Chang, H. [1 ]
机构：
[1] Univ Hlth Network, Toronto, ON, Canada
来源：
LABORATORY INVESTIGATION | 2014年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1922
引用
收藏
页码：468A / 469A
页数：2
相关论文
共 43 条
  • [21] BP-4-018, a novel inhibitor of STATs demonstrates anti-myeloma activity in preclinical models: Therapeutic implications of targeting aberrant STAT3 signaling in multiple myeloma
    Croucher, Danielle C.
    Li, Zhi Hua
    Page, Brent D. G.
    Wei, Ellen
    Gunning, Patrick T.
    Trudel, Suzanne
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [22] KS18, an Mcl-1 inhibitor, triggers cell death and enhances the therapeutic efficacy of venetoclax in bortezomib-resistant multiple myeloma cells
    Al Odat, Omar S.
    Aloudat, Osama
    Nelson, Emily
    Budak-Alpogan, Tulin
    Jonnalagadda, Subash
    Chen, Yong
    Pandey, Manoj
    CANCER RESEARCH, 2024, 84 (06)
  • [23] LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p
    Pan, Yafang
    Zhang, Yu
    Liu, Wenwen
    Huang, Yan
    Shen, Xianjuan
    Jing, Rongrong
    Pu, Jiang
    Wang, Xudong
    Ju, Shaoqing
    Cong, Hui
    Chen, Hongmei
    CELL DEATH & DISEASE, 2019, 10 (2)
  • [24] LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p
    Yafang Pan
    Yu Zhang
    Wenwen Liu
    Yan Huang
    Xianjuan Shen
    Rongrong Jing
    Jiang Pu
    Xudong Wang
    Shaoqing Ju
    Hui Cong
    Hongmei Chen
    Cell Death & Disease, 10
  • [25] Mir-137 and Mir-197 within Chromosome 1p Minimal Deletion Region Regulate Apoptotic Activity in Multiple Myeloma by Targeting MCL 1
    Yang, Yijun
    Onay, Venus
    Qi, Connie
    Saha, Manujendra N.
    Ning, Yi
    Chang, Hong
    BLOOD, 2012, 120 (21)
  • [26] Novel Targeting Of Phospho-Marcks Overcomes Drug Resistance and Induces Anti-Tumor Activity In Preclinical Models Of Multiple Myeloma
    Yang, Yijun
    Saha, Manujendra N.
    Chen, Yan
    Qiu, Lugui
    Reece, Donna E.
    Chang, Hong
    BLOOD, 2013, 122 (21)
  • [27] A same-day assay predicts apoptotic response to combined BCL-2 and MCL-1 BH3-mimetic targeting in multiple myeloma cells
    Grundy, Martin
    Al-Kaisi, Firas
    Cull, Joanna
    Williams, Cathy
    Smith, Dean
    Seedhouse, Claire H.
    EJHAEM, 2021, 2 (01): : 40 - 47
  • [28] Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
    Kuhn, Deborah J.
    Berkova, Zuzana
    Jones, Richard J.
    Woessner, Richard
    Bjorklund, Chad C.
    Ma, Wencai
    Davis, R. Eric
    Lin, Pei
    Wang, Hua
    Madden, Timothy L.
    Wei, Caimiao
    Baladandayuthapani, Veerabhadran
    Wang, Michael
    Thomas, Sheeba K.
    Shah, Jatin J.
    Weber, Donna M.
    Orlowski, Robert Z.
    BLOOD, 2012, 120 (16) : 3260 - 3270
  • [29] A novel Mcl-1 inhibitor induces cells death in a caspase-dependent manner and increases the efficacies of Venetoclax and ABT-737 in multiple myeloma cells
    Al-Odat, Omar S.
    Tripathi, Rahul S.
    Srivastava, Sandeep K.
    Gowda, Krishne
    Amin, Shantu G.
    Budak-Alpdogan, Tulin
    Jonnalagadda, Subash C.
    Pandey, Manoj K.
    CANCER RESEARCH, 2022, 82 (12)
  • [30] Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
    Challita-Eid, Pia M.
    Satpayev, Daulet
    Yang, Peng
    An, Zili
    Morrison, Karen
    Shostak, Yuriy
    Raitano, Arthur
    Nadell, Rossana
    Liu, Wendy
    Lortie, Dawn Ratay
    Capo, Linnette
    Verlinsky, Alla
    Leavitt, Monica
    Malik, Faisal
    Avina, Hector
    Guevara, Claudia I.
    Dinh, Nick
    Karki, Sher
    Anand, Banmeet S.
    Pereira, Daniel S.
    Joseph, Ingrid B. J.
    Donate, Fernando
    Morrison, Kendall
    Stover, David R.
    CANCER RESEARCH, 2016, 76 (10) : 3003 - 3013
12345